FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review

Stock Information for Zivo Bioscience Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Zivo Bioscience Inc.

CytoSorbents to Report Third Quarter 2024 Operating and Financial Results
CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update
CytoSorbents to Present at the H.C. Wainwright 26?? Annual Global Investment Conference
CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CytoSorbents Reports Second Quarter 2024 Financial and Operational Results
CytoSorbents Appoints Peter J. Mariani Chief Financial Officer
CytoSorbents to Report Second Quarter 2024 Operating and Financial Results
CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.